This year the KCRP is offering the Clinical Consortium – Clinical Trial Site Award (CTSA) mechanism to support the inclusion of new Clinical Trial Sites to the existing Kidney Cancer Research Consortium (KCRC). The FY20 KCRP CTSA is intended to support a major goal, a consortium of exceptional institutions and leading investigators to advance high-impact, novel therapeutic strategies and interventions to improve patient outcomes and significantly decrease the impact of the disease (the “Consortium”). The objectives of the Consortium shall be to design, develop, and conduct Phase I or Phase II-linked Phase I (Phase I/II) clinical trials of promising therapeutic agents for the prevention, detection/diagnosis, management, or treatment of kidney cancer. The KCRP CTSA provides the support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute investigator-initiated kidney cancer clinical trials. Support from this award is directed toward Consortium infrastructure needs rather than direct support of the research itself.
Applicants should be knowledgeable of the current state of clinical studies and clinical priorities related to kidney cancer and are encouraged to familiarize themselves with the KCRP Strategic Plan, and to consider this material when preparing their application.
The FY20 KCRP CTSA mechanism is designed to fund up to two new Clinical Trial Sites, each through separate awards. FY19 KCRP CTSA awardees are not eligible to apply for this FY20 KCRP CTSA. The Clinical Trial Sites will merge with the newly established KCRC and will be jointly responsible for proposing, selecting, and conducting Phase II and Phase I/II clinical trials focused on kidney cancer therapeutic interventions. The existing Consortium consists of one Coordinating Center and three Clinical Trial Sites.
The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and/or the American public.
Deadlines:
• Required Pre-Application Deadline: September 2, 2020
• Application Submission Deadline: September 23, 2020
Principal Investigators must be independent investigators at or above the level of Assistant Professor (or equivalent) at an eligible institution. Each investigator may be named on only one Clinical Consortium – Clinical Trial Site Award application as a PI. An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by, or affiliated with, an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY20 KCRP Clinical Consortium – Clinical Trial Site Award will not exceed $300,000 per year for a maximum of $600,000 for the entire 2-year performance period. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.
